

Dunn Report—Updates on Research February 2017

1. Hope for metastatic prostate cancer patients: targeted alpha therapy shows impressive results: MRI Can Rule Out Need for Biopsy in Men with High PSA:

http://www.medpagetoday.com/HematologyOncology/ProstateCancer/62780?xid=nl_mpt_Weekly_Education_2017-02-01&eun=g7057108d1r

2. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer:

<http://www.nature.com/articles/ncomms14248>

3. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial:

[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(16\)30661-1/fulltext](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext)

4. Hope for metastatic prostate cancer patients: targeted alpha therapy shows impressive results:

<https://ec.europa.eu/jrc/en/news/prostate-cancer-alpha-therapy-shows-impressive-results>
